With the launch of new single-cell sequencing platforms in 2026, the field stands at an exciting inflection point. This article surveys the most impactful advances in the field and discusses how they’re reshaping research in cancer, immunology, and beyond.
Introduction
Single-cell sequencing technologies have undergone remarkable advances over the past decade, transitioning from low-throughput experimental approaches to highly scalable platforms capable of profiling thousands to millions of cells simultaneously.1 From 2016 to 2018, droplet-based systems such as Drop-seq, ddSEQ Single-Cell Isolator, and the 10x Genomics Chromium platform emerged as dominant technologies owing to their ultra-high-throughput capacity and broad accessibility. Further advances led to the launch of microwell and nanowell-based systems, including BD RhapsodyTM and Takara Bio ICELL8, enabling work with fragile cells and visual cell selection. At the same time, plate-based methods such as SMART-seq2 and SMART-seq3 continued evolving to provide full-length transcript coverage and high-resolution detection of isoforms, splice variants, and mutations, while newer combinatorial barcoding approaches such as EvercodeTM enabled large-scale single-cell profiling without specialized microfluidic instruments.1
In the last four years, researchers have seen a major shift in single-cell sequencing technologies toward multiomics, spatial integration, and long-read full-length sequencing.2 Long-read platforms from Oxford Nanopore Technologies and PacBio enabled direct characterization of full-length transcripts, isoforms, and splicing events, representing a new wave of single-cell transcriptomic analysis.
At the beginning of this year, several product launches reshaped the market and steered more innovation. Among the most notable releases were Atera from 10x Genomics and Evercode WT v4 from Parse Biosciences.
Historical limitations in the field
Single-cell sequencing technologies differ in molecular resolution and throughput, reflecting a fundamental trade-off in the field. In general, the platforms are designed to balance scale (number of cells profiled) with depth (transcriptomic detail per cell). From a technological standpoint, droplet-based systems enable ultra-high throughput and lower cost per cell but typically provide lower transcript resolution.3 Microwell-based platforms offer intermediate sensitivity and flexibility but generally lower throughput than droplet systems.4 Plate-based methods deliver high-resolution, full-length transcript analysis, although with lower scalability and higher cost per cell.5 Long-read sequencing platforms add isoform and structural transcript information, yet still face trade-offs in throughput, cost, and accuracy.6
Despite rapid technological progress, key challenges remain including cost, data complexity, scalability, and the increasing difficulty of integrating heterogeneous datasets across platforms. Addressing these constraints will be critical for unlocking the full potential of single-cell analysis.
Key technological advances and transformative applications
Recent advances in single-cell sequencing are reshaping how complex biological systems are studied. Technologies are no longer differentiated solely by throughput or cost per cell, but by their ability to integrate diverse layers of biological information within the same experiment. Platforms that combine millions of cells per run with high-resolution transcriptomics, including isoform-level and long-read insights, while remaining computationally tractable, are setting the new standard.2,7
Specifically, 10x Genomics introduced Atera, a high-throughput spatially resolved single-cell platform designed to integrate spatial context with single-cell resolution, extending transcriptomic analysis beyond conventional dissociated-cell workflows. Illumina expanded the capabilities of the NovaSeq X through higher-throughput sequencing, improved multiomic support, and enhanced analytical integration, improving workflow standardization compared to earlier 3′-biased kits. Parse Biosciences’ Evercode v4/Penta pushed scalability further by eliminating microfluidics, enabling millions of cells per run. Meanwhile, Pacific Biosciences introduced the SPRQ-Nx platform, the next evolution in HiFi sequencing, to improve long-read throughput, while Oxford Nanopore Technologies expanded GridION Dx and nanopore RNA workflows, enabling full-length isoform and structural characterization beyond short-read platforms.
According to Amit Patel, Pacific Biosciences’ Sr. Director, Integrated Marketing, “Platforms like Atera are accelerating the field by adding tissue context and scale, while PacBio HiFi sequencing is complementary providing highly accurate full-length transcript reads, enabling researchers to resolve isoforms, splice variants, fusions, and expressed mutations that are difficult to capture with conventional short-read approaches.”
Cancer, immunology, and beyond
Together, the advances accelerated discoveries across diverse biomedical fields. For instance, cancer research could focus on tumor immune microenvironment and cellular heterogeneity, with increasing emphasis on spatial transcriptomics, biomarkers identification and T cell function.8 Single-cell sequencing supported the creation of a comprehensive transcriptional atlas of myeloid cells across several cancer types.9 Furthermore, integrating single-cell omics with artificial intelligence enabled the development of immune risk signatures and predictive scores for immunotherapy outcomes.10
In neurology, the technique has transformed the understanding of neuronal diversity and biomarker discovery for Alzheimer’s and Parkinson’s, revealing pathogenic mechanisms and therapeutic targets linked to genomic instability and neuroinflammation.11
Regarding infectious diseases, single-cell sequencing has advanced precision medicine by revealing cellular subpopulations linked to HIV resistance and biomarkers across tuberculosis stages.12 It has also characterized COVID-19 immune signatures, associating severe disease with cytokine storm and T-cell exhaustion, and enabled the generation of Plasmodium transcriptomic atlases that could identify vaccine and antimalarial targets.11 More broadly, single-cell sequencing has also enabled the development of therapies targeting shared pathogenic mechanisms, such as cellular exhaustion and interferon pathway dysregulation.12
Remaining challenges and what comes next
The scale–sensitivity trade-off remains a persistent challenge, although successive product launches continue to improve performance. Another major limitation is the massive volume of data generated by single-cell sequencing experiments, which are difficult to store, process, and interpret. This issue is further amplified by the current push to integrate single-cell, spatial, and multiomic datasets into unified biological frameworks.
“One of the biggest barriers to integration is the growing heterogeneity of biological datasets—different resolutions, sample types, preparation methods, and experimental conventions often make data integration and interpretation quite difficult”, says Josephine Lee, Senior Director, Assay Productization & Single Cell Biology at 10x Genomics.
Continued advances in AI are expected to ease this integration soon.2,7 Lee emphasizes that AI is increasingly automating complex biological data analysis workflows, improving reproducibility and scalability. However, standardization, preservation of biological context, and expert-guided model development remain essential, particularly for multiomic datasets.
Cost also remains a barrier to the widespread adoption of single-cell sequencing, alongside infrastructure limitations required for large-scale implementation. According to Laura Tabellini from Parse Biosciences, “The cost concern has not gone away completely, but today the bottleneck is infrastructure”. She argues that large research facilities can manage the enormous amount of data generated by ScRNA-seq but for clinical translation it is still difficult to manage a high demand for computational capacity, cloud storage and data management systems.
Overall, these challenges are expected to be progressively mitigated as the field evolves to integrate scale, resolution, single-cell sequencing, spatial analysis, and AI shaping the next generation of single-cell sequencing technologies. Advances in multiomics, spatial transcriptomics, and computational approaches are now established and priority should be strengthening links between clinical application, basic research, technological development, and standardization.
References
1. Wu X, Yang X, Dai Y, et al. Single-cell sequencing to multi-omics: technologies and applications. Biomark Res. 2024;12(1):110. doi:10.1186/s40364-024-00643-4
2. Kashima Y, Sakamoto Y, Kaneko K, Seki M, Suzuki Y, Suzuki A. Single-cell sequencing techniques from individual to multiomics analyses. Exp Mol Med. 2020;52(9):1419-1427. doi:10.1038/s12276-020-00499-2
3. Macosko EZ, Basu A, Satija R, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell. 2015;161(5):1202-1214. doi:10.1016/j.cell.2015.05.002
4. Gierahn TM, Wadsworth MH, Hughes TK, et al. Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. Nat Methods. 2017;14(4):395-398. doi:10.1038/nmeth.4179
5. Picelli S, Faridani OR, Björklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171-181. doi:10.1038/nprot.2014.006
6. Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 2020;21(1):30. doi:10.1186/s13059-020-1935-5
7. Stein CM, Weiskirchen R, Damm F, Strzelecka PM. Single-cell omics: Overview, analysis, and application in biomedical science. J Cell Biochem. 2021;122(11):1571-1578. doi:10.1002/jcb.30134
8. Li Z, Han Q, Huang Z, et al. Exploring research trends in cancer immunotherapy via single-cell technologies: a scientometric perspective. Front Immunol. 2025;16:1640224. doi:10.3389/fimmu.2025.1640224
9. Cheng S, Li Z, Gao R, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792-809.e23. doi:10.1016/j.cell.2021.01.010
10. Ye B, Jiang A, Liang F, Wang C, Liang X, Zhang P. Navigating the immune landscape with plasma cells: A pan-cancer signature for precision immunotherapy. BioFactors. 2025;51(1):e2142. doi:10.1002/biof.2142
11. Wang X, Li N, Wang W, Liu B. Single-cell sequencing: accurate disease detection. Clin Transl Oncol. 2025;28(2):404-423. doi:10.1007/s12094-025-04007-8
12. Lyu M, Liu Y, Zhou J, et al. Advances in Single‐Cell Sequencing for Infectious Diseases: Progress and Perspectives. Advanced Science. 2025;12(32):e15678. doi:10.1002/advs.202415678
About the author: Luiza Erthal, Ph.D., is a former biomedical scientist who found her passion in communicating science in different formats. She graduated in Biomedical Sciences in 2014 (UFRJ- Brazil), then she completed a Masters in Biochemistry in 2016 (UFRJ-Brazil) and a Ph.D. in Pharmaceutical Sciences in 2021 (TCD-Ireland). She works as a freelance medical writer writing for blogs, health & science companies, and universities. She loves to talk about science and share research findings with other people. Her mission is to write about science to empower people and make their lives better.